SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta shares are surging double digitstheir largest single-day gain in yearsas traders point to rapid adoption of the Muse AI agent, a Wells Fargo price-target hike, and positioning ahead of the Meta Connect conference. Sentiment is split between bulls celebrating Muse's app-store momentum and bears calling the move hype-driven and overbought, with some expecting a sell-the-news reaction at Connect and others flagging Amazon's block of Muse from its shopping site.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as traders vent over the stock trading flat to lower during a broad market rally while fintech peers like Robinhood surge, renewing debate over whether the shares are undervalued or structurally impaired by dilution and leadership criticism. Heavy attention is also on Citizens Bank's lawsuit accusing SoFi of racketeering over the poaching of mortgage employees, which some traders dismiss as a legal scare tactic while others believe it has merit.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals is surging after President Trump announced a U.S.-Denmark-Greenland security agreement that traders see as de-risking and potentially accelerating development of the company's Tanbreez rare-earth project, driving a broader rally in Greenland-linked stocks. Extremely bullish sentiment is amplified by heavy short interest and squeeze speculation, while skeptics counter that the pact grants no mining rights and warn of sell-the-news risk around the planned Trump-Xi meeting on critical minerals.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending on reports that it reached a settlement with California and other state attorneys general whose lawsuit had blocked its merger with Warner Bros. Discovery, clearing a major legal hurdle for the deal. Community reaction is mixed: bulls treat the merger as effectively cleared and speculate about a short squeeze, while skeptics point to the lack of official confirmation, criticize settlement terms such as editorial oversight commitments, and flag persistent selling pressure despite the headlines.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging to record highs and briefly crossing the trillion-dollar market-cap milestone amid a broad semiconductor rally driven by AI demand, with peers like Intel and Arm gaining sharply as well. Community reaction is split, with bulls celebrating the milestone and eyeing further upside while bears call the move overextended on stretched valuation, and some traders locking in profits or opening short positions.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk shares slid after its Capital Markets Day, where long-term pipeline targets through 2035 and revenue growth guided only "in line with peers" failed to ease concerns over semaglutide patent expirations and competition from Eli Lilly. Reaction is split between bears faulting CEO Mike Doustdar's communication and the muted growth outlook, and dip-buyers calling the selloff an overreaction at historically low valuations.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X ETF

SOXS is trending as it slides sharply alongside a strong semiconductor rally, drawing heavy dip-buying from traders positioning for an eventual reversal in the AI-driven chip trade, while others warn the leveraged ETF's structural decay makes holding it a losing battle. The debate pits bears citing hawkish rate-hike expectations, inflation, and AI-bubble concerns against bulls mocking the short thesis as the sector keeps climbing.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Traders are driving Dogecoin sharply higher as it presses against the psychological $0.10 resistance level, with bulls urging continued buying to force a breakout and bears warning that longtime holders could sell heavily into any move above it. The rally is playing out against broader crypto momentum tied to Bitcoin's direction and reaction to the Senate's failure to pass the Clarity Act, with the CFTC saying it will still move forward with its own crypto rules.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Traders are attributing the stock's rally to a partnership placing Shop Pay inside Meta's Muse AI shopping assistant to enable agentic checkout across Shopify stores, with no financial terms or rollout timing disclosed. Reaction is split between bulls touting the merchant-wide scale of the integration and skeptics warning that AI shopping agents could disintermediate e-commerce platforms, while the stock also attempts to reclaim its 200-day moving average.

Daily surprises, near and far. Your source for travel inspiration and more. Travel moves you!

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Paramount Skydance's reported settlement with California and other states that sued to block its acquisition of Warner Bros. Discovery has cleared a major legal hurdle, sending WBD sharply higher. The community is celebrating the rally while debating whether to lock in gains or hold through the expected closing, with some cautioning that the state AG called the settlement no endorsement of the merger and a separate Writers Guild lawsuit remains pending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer PR Newswire SYDNEY...

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances...

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing...

Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering PR Newswire SYDNEY, Aug. 31, 2026 Company to host a corporate update call Tuesday, September 1st at...

Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering

Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering PR Newswire SYDNEY, Aug. 28, 2026 SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited(NASDAQ: KZIA) ("Kazia" or the...

Kazia Therapeutics Limited Announces Proposed Public Offering

Kazia Therapeutics Limited Announces Proposed Public Offering Kazia Therapeutics Limited Announces Proposed Public Offering PR Newswire SYDNEY, Aug. 27, 2026 SYDNEY, Aug. 27, 2026 /PRNewswire/ -- Kazia Therapeutics Limited(NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology...

Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer

Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer PR Newswire SYDNEY, Aug. 27, 2026 Durable...

The Multi-Billion-Dollar Race to Defeat Glioblastoma: Why Investors Are Watching One of Oncology's Most Challenging Frontiers

Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. $NTHI, $KZIA, $BNTX, $IBRX

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

Kazia Therapeutics Appoints James Levine as Chief Financial Officer Kazia Therapeutics Appoints James Levine as Chief Financial Officer PR Newswire SYDNEY, June 2, 2026 SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a...

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer PR Newswire SYDNEY, May 26, 2026 Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging...

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Limited - ADR

KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show?

Equity

Bearish Sentiment

Rising interest rates

Surging bond yields

Oil/energy volatility

Trump/political risk

U.S. investors are navigating a stacked macro backdrop, with the Federal Reserve hiking rates for the first time since July 2023, the 10-year Treasury yield hitting 5.00% - its highest level since 2007 - and oil prices swinging between $94 and $105 a barrel amid the ongoing U.S.-Iran conflict and Saudi pipeline disruptions. What's the biggest risk to your portfolio right now? Vote and explain your reasoning in the comments.

With the Fed hiking rates for the first time since 2023, the 10-year Treasury yield near 5%, and oil prices swinging on the U.S.-Iran conflict, what&#39;s the biggest risk to your portfolio right now?

Stocktwits

With the Fed hiking rates for the first time since 2023, the 10-year Treasury yield near 5%, and oil prices swinging on the U.S.-Iran conflict, what's the biggest risk to your portfolio right now?

Feed

News

Sentiment

Fundamentals

Info

KZIA Kazia Therapeutics

Fundamentals

Latest KZIA News